Perspective Therapeutics (CATX) Depreciation & Amortization (CF) (2010 - 2026)

Perspective Therapeutics has disclosed Depreciation & Amortization (CF) across 17 years of filings, most recently posting $1.1 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $1.1 million, up 53.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.6 million (up 35.91% YoY), and the FY2025 annual result was $3.3 million, up 40.98% from the prior year.
• Depreciation & Amortization (CF) came in at $1.1 million for Q1 2026 at Perspective Therapeutics, up from $1.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.1 million in Q1 2026 to a low of $67000.0 in Q3 2022.
• The 5-year median for Depreciation & Amortization (CF) is $356000.0 (2024), against an average of $473117.6.
• Across the five-year window, Depreciation & Amortization (CF) increased 13.56% in 2022 and surged 286.57% in 2023, its largest moves.
• Perspective Therapeutics' Depreciation & Amortization (CF) stood at $138000.0 in 2022, then jumped by 118.84% to $302000.0 in 2023, then surged by 134.77% to $709000.0 in 2024, then surged by 42.6% to $1.0 million in 2025, then increased by 11.37% to $1.1 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.1 million (Q1 2026), $1.0 million (Q4 2025), and $775000.0 (Q3 2025), per Business Quant data.